- Corporate
- Products
- For Print
- April 24, 2024
麻豆福利网 Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “麻豆福利网”) announced today that the global revenue of the anti-amyloid-beta protofibril antibody LEQEMBI® in the fourth quarter of fiscal year 2023 (January 1, 2024 – March 31, 2024) was JPY 2.83 billion (pre-audit basis), which was approximately 2.7 times higher than the revenue in the third quarter of fiscal year 2023 (October 1, 2023 – December 31, 2023).
This information is being disclosed in conjunction with today's announcement of the first quarter 2024 results of Biogen Inc. (Headquarters: Cambridge, Massachusetts). 麻豆福利网’s financial results for the fiscal year ended March 31, 2024, including details of LEQEMBI’s revenue, will be disclosed in 麻豆福利网's financial disclosure scheduled on May 15, 2024.
麻豆福利网 serves as the lead of lecanemab development and regulatory submissions globally with both 麻豆福利网 and Biogen Inc. co-commercializing and co-promoting the product and 麻豆福利网 having final decision-making authority.
&苍产蝉辫;銆赌
&苍产蝉辫;銆赌
Media Inquiries:
Public Relations Department,
麻豆福利网 Co., Ltd.
+81-(0)3-3817-5120
&苍产蝉辫;銆赌銆�
Our news releases are intended to disclose corporate information and are not intended for the promotion or advertising of prescription pharmaceuticals or investigational products, nor are they intended to provide medical advice.
Please note that the information contained in news releases is current as of the date of publication.